SMI
12 948,60
|
140,52
|
1,10%
|
Analysen zu SMI-Werten
10.02.25 | Roche Sell | Goldman Sachs Group Inc. | |
10.02.25 | Roche Outperform | Bernstein Research | |
07.02.25 | UBS Halten | DZ BANK | |
07.02.25 | ABB Kaufen | DZ BANK | |
07.02.25 | UBS Overweight | JP Morgan Chase & Co. | |
06.02.25 | Nestlé Neutral | UBS AG | |
06.02.25 | Novartis Neutral | Goldman Sachs Group Inc. | |
06.02.25 | Roche Sell | Goldman Sachs Group Inc. | |
06.02.25 | UBS Buy | Goldman Sachs Group Inc. | |
05.02.25 | Zurich Insurance Hold | Deutsche Bank AG | |
05.02.25 | Nestlé Market-Perform | Bernstein Research | |
04.02.25 | Roche Sell | Deutsche Bank AG | |
04.02.25 | UBS Buy | Goldman Sachs Group Inc. | |
04.02.25 | UBS Hold | Deutsche Bank AG | |
04.02.25 | UBS Overweight | JP Morgan Chase & Co. | |
04.02.25 | Novartis Buy | Deutsche Bank AG | |
04.02.25 | UBS Outperform | RBC Capital Markets | |
04.02.25 | UBS Buy | Goldman Sachs Group Inc. | |
03.02.25 | Roche Underweight | JP Morgan Chase & Co. | |
03.02.25 | Novartis Hold | Deutsche Bank AG | |
03.02.25 | Novartis Kaufen | DZ BANK | |
03.02.25 | Nestlé Neutral | UBS AG | |
03.02.25 | Novartis Buy | UBS AG | |
31.01.25 | Roche Sell | Deutsche Bank AG | |
31.01.25 | Novartis Neutral | Goldman Sachs Group Inc. | |
31.01.25 | Novartis Buy | UBS AG | |
31.01.25 | ABB Sell | Deutsche Bank AG | |
31.01.25 | Roche Neutral | UBS AG | |
31.01.25 | UBS Overweight | JP Morgan Chase & Co. | |
31.01.25 | Novartis Outperform | Bernstein Research | |
31.01.25 | Novartis Hold | Jefferies & Company Inc. | |
31.01.25 | ABB Neutral | UBS AG | |
30.01.25 | Roche Outperform | Bernstein Research | |
30.01.25 | ABB Underperform | Bernstein Research | |
30.01.25 | Roche Underweight | JP Morgan Chase & Co. | |
30.01.25 | ABB Neutral | UBS AG | |
30.01.25 | Roche Neutral | UBS AG | |
30.01.25 | Roche Sell | Goldman Sachs Group Inc. | |
30.01.25 | ABB Neutral | Goldman Sachs Group Inc. | |
30.01.25 | ABB Sector Perform | RBC Capital Markets |
HOT STOCKS DER LETZTEN 3 TAGE
Zurich Insurance | 7 |
Roche | 3 |
UBS | 1 |
Novartis | 1 |